Cancer, Preterm Births, and Specialty Drugs Drive Record Severity in Self-Funded Health Plans

High-cost claim frequency has nearly tripled over five years and severity accelerated sharply in 2025, according to QBE North America's 2026 Accident & Health Market Report.
By: | June 30, 2026
Neonatal intensive care unit at night

Claims exceeding $1 million have become dramatically more common in employer-sponsored health plans, with frequency nearly tripling over the past five years and average severity in 2025 running 10% above the average of prior years, according to QBE North America’s 2026 Accident & Health Market Report.

The insurer’s analysis of its medical stop loss portfolio found that jumbo claim frequency rose across all severity thresholds from 2024 to 2025, with claims exceeding $500,000, $750,000, $1 million, and $2 million all increasing, signaling what the report described as “a broad-based shift rather than isolated volatility.”

Cancer and Preterm Births Concentrate Risk at Higher Deductibles

Neoplasms, or more commonly known as tumors, remain the single largest driver of excess claims, accounting for 31% to 36% of stop loss claim reimbursements across all years studied.

The financial profile of cancer care has changed materially, the report said. Earlier use of specialty oncology drugs, including immunotherapies and cellular therapies, combined with longer and more complex treatment courses, has elevated cumulative spend per claimant. QBE reported its highest single claim to date exceeded $7 million, driven by complex oncology care that progressed to transplant and advanced cellular therapy.

Blood cancers carry a disproportionate share of that burden, the report said. At a $1 million individual specific deductible, hematologic malignancies represented more than half of all neoplasm claims, the report found. Claim cost per employee per month for blood cancers rose more than 70% in 2025, with myeloid leukemia showing the steepest increase. Potential annual costs for conditions such as multiple myeloma range from $335,000 to $2.5 million, depending on treatment pathway and site of care.

Preterm births emerged as another accelerating pressure point for self-funded health plans, QBE reported. Birth-related claim frequency more than doubled from 2024 to 2025, the report noted, and four of the top six pediatric claims in QBE’s 2025 experience stemmed from extensive hospitalizations following birth.

The range of third-party administrator payments for costly pediatric claims ran from $10,600 to $5.6 million. One claimant treated with Elevidys for Duchenne muscular dystrophy incurred approximately $3.4 million in paid claims, illustrating the financial impact of gene therapies now entering pediatric treatment pathways.

Severity in 2025 Driven by Documentation and Pricing, Not Utilization Alone

The report identified two converging forces behind the 2025 severity spike that are distinct from changes in how often care is used. First, clinical complexity during extended inpatient stays is now being captured more comprehensively, particularly for oncology, neonatal care, and advanced cardiac cases. The report characterized this as more complete acuity documentation rather than increased prevalence, but noted it has elevated the reimbursement severity of individual claims.

Second, provider reimbursement structures shifted materially. Renegotiated hospital contracts, driven by sustained labor costs and rising operating expenses, raised inpatient rates across many health systems. Hospital services consumer price index rose to 7.3% in the most recent quarter tracked, compared to a physicians’ services CPI that remained far lower.

Hospital care accounted for 40% of the growth in national health spending between 2022 and 2024, the report noted, citing KFF data showing total national health spending grew from $4.6 trillion in 2022 to $5.3 trillion in 2024.

Specialty Pharmaceuticals Create Long-Tail Liability

Specialty drugs have moved from an emerging concern to an embedded, long-duration financial exposure, the report said. Many high-cost therapies are designed for long-term or lifelong use, with discontinuation rare once treatment begins, QBE noted.

Annual costs for commonly prescribed specialty drugs in QBE’s portfolio ranged from $90,000 for Rinvoq to $395,000 for Opdivo. For rare disease therapies, single-member annual costs can reach $2.1 million or more, as is the case with Nexviazyme, an enzyme replacement therapy for Pompe disease.

The report said overall U.S. pharmaceutical expenditures grew 12.7% in 2025 to $915.2 billion, citing published research. GLP-1 medications alone are expected to account for 0.5% to 1% of estimated medical cost trend in 2026. Inpatient behavioral health claims were up nearly 80% from early 2023 to the end of 2024, with trend increases of 10% to 20% anticipated for 2026, the report added.

Obtain the full report here.

The R&I Editorial Team can be reached at [email protected].

More from Risk & Insurance